AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04932421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABC of Emotions
Description: ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders).
Study NCT06583226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with suture and cyanoacrylate
Description: The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
Study NCT06583226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with suture and cyanoacrylate and coconut oil application
Description: Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) and coconut oil (test group)
Study NCT05492097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Traditional exercise therapy and NMES
Study NCT05492097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy and Robotic Walking Training
Description: Traditional exercise therapy and Robotic Walking Training
Study NCT05547321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMTX705
Description: The investigational product is OMTX705 administered as monotherapy.
Study NCT05547321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The investigational product is OMTX705 administered in combination with pembrolizumab.
Study NCT05522465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 4mg/kg.d, d1-4
Study NCT05522465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.6mg/kg.d, d1-4
Study NCT06175871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTAGO exercises
Description: Exercices for improvement postural control and mobility and decrease falls risks
Study NCT06175871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Exercice and education from physical therapy practice conventional from Hospital.
Study NCT04433858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: open-label
Study NCT04830813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
Study NCT04830813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
Study NCT04679077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cytocam-IDF imaging device
Description: Observation of the microcirculation
Study NCT06468189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct stimulation
Description: Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
Study NCT05187104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured retinal stem and progenitor cells
Description: Cultured retinal stem and progenitor cells injected subretinally
Study NCT05187104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of age-related macular degeneration according to the clinical protocols
Study NCT05187104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of age-related macular degeneration according to the clinical protocols
Study NCT06468189 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The same device used for stimulation will be used, but no stimulation will be given.
Study NCT05702190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opium tincture
Description: Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
Study NCT05702190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
Study NCT06516211 — intervention group
Intervention type: DEVICE
Intervention: Clara Pregnancy Test
Description: Multi-Level Pregnancy Test
Study NCT04613752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diaphragmatic function measurements and diaphragmatic ultrasound
Description: A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
Study NCT06111599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar sympathetic blockade
Description: Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
Study NCT04876261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia® bitter
Description: * ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein
Study NCT04876261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oliphenolia®
Description: * ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein
Study NCT04876261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol
Description: * extra virgin olive oil~* 5 mg hydroxytyrosol
Study NCT06516211 — intervention group
Intervention type: DEVICE
Intervention: Professional Marketed Pregnancy Test
Description: Early Pregnancy Test
Study NCT06117163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Model
Description: The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication.
Study NCT04701931 — intervention group
Intervention type: DEVICE
Intervention: Maestro2 OCTA
Description: The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
Study NCT04701931 — intervention group
Intervention type: DEVICE
Intervention: Cirrus HD-OCT 5000
Description: The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
Study NCT04701931 — intervention group
Intervention type: DEVICE
Intervention: TRC-50DX
Description: The TRC-50DX retinal camera images the fundus used for diagnostic purposes
Study NCT04784208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for Thyroid stimulating hormone (TSH)
Description: Blood test for Thyroid stimulating hormone (TSH)
Study NCT05850455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride 'Precedex' combined with
Description: Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
Study NCT05850455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'
Description: The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
Study NCT05850455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
Study NCT05850455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local infiltration with Lidocaine HCL 1%'Debocaine'
Description: Lidocaine 1% which is a local analgesic as local infiltration
Study NCT05056909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney ACTion
Description: AI-supported software for chronic kidney disease care
Study NCT05056909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04882072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Participants will receive IV infusion and SC injection of ustekinumab.
Study NCT05022758 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: One of NOAC (Non-vitamin K antagonist oral anticoagulants)
Study NCT05022758 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: One of OAC (Oral anticoagulation therapy)
Study NCT04882072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive IV infusion and SC injection of ustekinumab.
Study NCT04852029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dose hCG
Description: Patients will either maintain the current dose of have an increased dose prescribed based on randomization
Study NCT04852029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose hCG
Description: Patients will either maintain the current dose of have an increased dose prescribed based on randomization
Study NCT04882072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion and SC injection of matching placebo.
Study NCT04882072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucorticoid Taper Regimen
Description: Glucocorticoid will be administered orally.
Study NCT04882072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucorticoid Taper Regimen
Description: Glucocorticoid will be administered orally.
Study NCT05881538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
Study NCT05929794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 0.75% Topical Gel
Description: Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
Study NCT05929794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 0.75% Topical Cream
Description: Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
Study NCT05929794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal water loss measurement
Description: Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
Study NCT05929794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Resistance
Description: Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
Study NCT05929794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin color measurement
Description: Baseline measurements of skin color will be made at 3 sites on the upper arm.
Study NCT05929794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micropatch application
Description: All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
Study NCT05915260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion
Description: This is a observational follow up study accordingly all subjects will undergo the same examinations
Study NCT04607135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI)
Description: Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system
Study NCT04607135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Study NCT06049719 — intervention group
Intervention type: OTHER
Intervention: NIH Task Force's Recommended Multidimensional Minimal Dataset
Description: Questionnaire
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (80 mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin (80 mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study NCT05807464 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-15)
Study NCT05557838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)
Study NCT05557838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)
Study NCT04936646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RepetitiveTranscranial Magnetic Stimulation (rTMS)
Description: The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
Study NCT04936646 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RepetitiveTranscranial Magnetic Stimulation (rTMS)
Description: The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
Study NCT06535620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: red wine with alcohol
Description: 200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
Study NCT06535620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: red wine without alcohol
Description: 200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
Study NCT05660811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: short postimplantation dual antiplatelet therapy
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
Study NCT05660811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: extended postimplantation dual antiplatelet therapy
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months